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ORIGINAL ARTICLE
Pharmacogenomics and microarrays are two of
the most important scientific breakthroughs of
the last decade and have great potential in detec-
tion and treatment of diseases, and many other
applications. On the other hand, because of ge-
netic variations and genetic-by-environmental in-
teraction, patients respond differently to the same
treatment or therapeutic regimen. After comple-
tion of the Human Genome Project (HGP), dis-
ease targets at the molecular level have been
identified. Thus, biochip products based on heri-
table DNA markers, mutations, and expression
patterns for detection of diseases have become
possible. One of the unique characteristics is that
they are in vitro diagnostic devices composed of
multiple parallel assays for multiple markers as-
sayed simultaneously. In addition, one of the fea-
tures of these in vitro diagnostic devices is their
ability to classify patients through their molecular
signature into the following four categories: (1)
treatment is efficacious without toxicity; (2) treat-
ment is efficacious with toxicity; (3) treatment is
not efficacious without toxicity; and (4) treat-
ment is not efficacious with toxicity. As a result,
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these in vitro diagnostic devices based on multiple
DNA markers, mutations, and expression patterns
are referred to as genomic composite biomarker
classifiers (GCBCs).
However, the quality performance of GCBCs
varies.1–3 For example, Ma et al4 suggested the
use of the ratio of the expression levels of two
genes for prediction of clinical outcome in pa-
tients with early-stage breast cancer after receiv-
ing tamoxifen. However, their findings have not
been reproduced by other investigators.5 On the
other hand, for evaluating the risk of recurrence
in patients with early-stage breast cancer treated
with hormonal therapy, the Oncotype DX breast
cancer assay uses the expression levels of 21 genes
measured by RT-PCR.6,7 However, MammaPrint®
assesses the risk of distant metastasis determined
by the molecular signature provided by a 70-
gene microarray. The diagnostic results provided
by the GCBCs are not only important for the
prognosis and prediction of clinical outcomes,
but are also vital for selection of the optimal
treatment modality. Therefore, the quality per-
formance of the GCBCs becomes crucial. Con-
sequently, the US Food and Drug Administration
(FDA) recently issued the following guidance to
ensure the quality of GCBCs: (1) Gene Expression
Profiling Test System for Breast Cancer Prognosis
(9 May 2007); (2) Pharmacogenetic Tests and Genetic
Tests for Heritable Markers (19 June 2007); (3) In
Vitro Diagnostic Multivariate Index Assays (26 July
2007); and (4) Statistical Guidance on Reporting
Results from Studies Evaluating Diagnosis Tests (13
March 2007).
Among the many issues with regard to the
quality performance of GCBCs, we focused only
on the following three fundamental subjects: se-
lection of differentially expressed genes, agreement
of measurements of expression levels between
technical replicates, and reproducibility between
laboratories.
As demonstrated above, the number of genes
or biomarkers varies from one GCBC to another.
Therefore, the first task for development of a GCBC
is to identify the molecular markers that truly
differentiate patients with different molecular
signatures, which can predict clinical outcomes
or can correlate with responses to treatments. Tra-
ditional statistical approaches to identify differ-
entially expressed genes only consider statistical
significance. However, a gene identified by statis-
tical significance does not imply that it is of any
biological importance or can classify patients with
different clinical outcomes or treatment responses.
Therefore, we suggest that statistical formulation
for the hypothesis on identification of differen-
tially expressed genes must take into consideration
the biological meaning and statistical significance
simultaneously.
The Pearson correlation coefficient (PCC) is
the most commonly employed statistical tool for
evaluation of agreement of measurements of ex-
pression levels between technical replicates of
the same gene, from the same sample, under the
same operating conditions. PCC is an excellent
measure for detection of linear associations, and it
remains unchanged if the measurements of expres-
sion levels are added or multiplied by a constant.
In other words, it is location and scale invariant.
However, agreement of the measurements of ex-
pression levels between technical replicates re-
quires reflection of changes in both means and
variability. Therefore, the PCC cannot be used to
assess agreement of gene expression levels be-
tween technical replicates. We suggest using the
concordance correlation coefficient (CCC)8 to
evaluate the agreement of measured expression
levels between technical replicates of the same
genes, from the same samples, under the same
operating conditions. On the other hand, for as-
sessment of reproducibility between laboratories,
the between-laboratory and between-sample vari-
ability are the most important sources of varia-
tion.9 Therefore, based on the intraclass correlation
coefficient (ICC), we propose formulating a hy-
pothesis for assessment of reproducibility between
laboratories under a two-way random effects model
without interaction. For these three fundamental
quality performance issues for GCBCs, we first
state the corresponding statistical hypothesis. The
statistical methods are then presented with either
the simulation results or numerical examples.
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Materials and Methods
Currently, most available statistical methods for
identification of differentially expressed genes, in-
cluding the t test,10 permutation t test,11 or signif-
icance analysis of microarray (SAM),12 are based
on the traditional hypothesis of equality. However,
the hypothesis of equality can only detect whether
the difference in the average expression levels is
zero between groups of patients with different
molecular signatures. Thus, it fails to take into
account the magnitude of biologically meaning-
ful fold changes. In addition, the false-positive rate
for identifying differentially expressed genes can
be very high because of simultaneously testing
tens of thousands of genes at the same time with
a small number of samples.
In order to include the magnitude of biologi-
cal meaningful fold change in the formulation of
statistical hypothesis, we define a non-differential
zone in which the expression level of a gene can-
not distinguish between two groups of patients
with different molecular signatures. The upper
boundary of the non-differential zone is a minimal
biologically meaningful upper threshold above
which a gene is overexpressed (overexpressed
zone). Similarly, the lower boundary of the non-
differential zone is a maximal biologically mean-
ingful upper threshold under which a gene is
underexpressed (underexpressed zone). A gene is
said to be differentially expressed between two
groups of patients if the difference in the average
expression levels between the two groups is either
larger than a minimal biologically meaningful
upper threshold or smaller than a maximal bio-
logically meaningful lower threshold. Based on
this concept, Liu and Chow13 formulated a hypo-
thesis for identifying the differentially expressed
genes as the interval hypothesis, by simultaneously
taking both the minimal biologically meaning-
ful fold changes and statistical significance into
consideration. The null hypothesis of the inter-
val hypothesis is the non-differential zone. On the
other hand, the alternative hypothesis of the in-
terval hypothesis consists of both overexpressed
and underexpressed zones. Based on the interval
hypothesis, a two one-sided tests (TOST) proce-
dure has also been suggested by Liu and Chow.13
However, the structures of the correlations of the
expression levels of the different genes are not
incorporated in their proposed TOST procedure,
which requires the normality assumption. There-
fore, Liu et al14 proposed applying the multivari-
ate permutation method to improve the TOST
procedure (permuted TOST procedure).
The CCC can be represented as a ratio. The
numerator is the covariance of the expression
levels between two technical replicates. The de-
nominator is the sum of variances of the expres-
sion levels of two technical replicates, plus the
square of the difference of the average expression
levels between two technical replicates. The range
of CCC is from −1 to 1. A CCC of 1 indicates a per-
fect positive agreement and a CCC of −1 implies
a perfect negative agreement. On the other hand,
a CCC of 0 reveals no agreement. Liao et al15
proposed a noninferiority hypothesis for evalua-
tion of agreement of expression levels between
two technical replicates. The null hypothesis of
the noninferiority hypothesis is that CCC is less
than a minimal threshold for agreement, say 0.9,
while the alternative hypothesis is that CCC is
greater than the minimal threshold of CCC for
agreement. The null hypothesis is rejected and
agreement of expression levels between technical
replicates can be claimed at the 5% significance
level if the lower 95% confidence limit for CCC
is greater than the minimal threshold. The con-
fidence limit for CCC can be constructed using
either the asymptotic approach8 or by the method
of generalized pivotal quantities (GPQ).16
For evaluation of reproducibility between
laboratories, a two-way random-effects model 
is employed to estimate the between-laboratory,
between-sample and the error variances. The ICC
is the ratio of the between-laboratory variance 
to the total variance, which is the sum of the 
between-laboratory, between-sample, and error
variances. The range of ICC is from 0 to 1. An ICC
of 1 implies a perfect reproducibility. Again, a non-
inferiority hypothesis is used to assess the between-
laboratory reproducibility. The null hypothesis of
the noninferiority hypothesis is that the ICC is
no greater than the minimal threshold of ICC for 
reproducibility, say 0.5. On the other hand, the
alternative hypothesis is that the ICC is greater
than the minimal threshold. The null hypothesis
of the noninferiority hypothesis is rejected, and
the between-laboratory reproducibility can be con-
cluded at the 5% significance level if the lower 95%
confidence limit for ICC is greater than the min-
imal threshold. The confidence limit for CCC
can be constructed using either the modified large
sample (MLS) approach17 or by the GPQ method
which can handle the imbalances. Technical details
of the GPQ for ICC can be obtained from the 
authors upon request.
Results
Example 1: identification of differentially
expressed genes
The data set of Luo et al18 was used to illustrate
application of the TOST and permuted TOST meth-
ods. It consisted of normalized gene expression
ratios obtained from a collection of 25 prostate
tissue samples comprising 16 prostate cancers and
nine benign prostatic hyperplasia (BPH) speci-
mens. The data were obtained from http://research.
nhgri.nih.gov/microarray/prostate/supplement/
images/6500GeneListw=CRs&QSs.xls. A common
reference design was used for this series of exper-
iments. A total of 5854 genes with quality scores
greater than zero for at least three prostate cancer
specimens and three BPH specimens were used
in the analysis. Log-transformation (base 2) was
the scale used for analysis. For the purpose of illus-
tration, the non-differential zone for a gene be-
tween the prostatic cancer and BPH was [−1, 1] on
the log scale. In other words, a gene was differen-
tially expressed between the patients with prostatic
cancer and those with BPH if its true fold change
was greater than 2 or smaller than 1/2.
The results of the TOST based on the interval
hypothesis with the minimal biologically mean-
ingful threshold of 1 (log2 base) are presented in
Figure 1. At the 5% nominal significance level,
there were a total of 47 genes (0.8%) with p val-
ues calculated from the TOST procedure < 0.05.
As can be seen in Figure 1, the minimal observed
fold change with p < 0.05 obtained from the
TOST procedure was > 2.83 (i.e. 1.5 log2). How-
ever, as mentioned above, the TOST is based on
the normal assumption and does not consider the
correlation structures of expression levels among
genes. Therefore, as demonstrated by this example,
it can be quite conservative in the identification
of differentially expressed genes. Figure 2 provides
the results of the permuted TOST procedure. A
total of 181 genes were identified as differentially
expressed by the permuted TOST procedure at
the 5% significance level. The interval hypothesis
Genomic composite biomarker classifiers
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Figure 1. Results of the TOST procedure.
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Figure 2. Results of the permuted TOST procedure.
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directly takes into consideration the minimal bi-
ologically meaningful threshold; therefore, these
181 differentially expressed genes identified by the
permuted TOST not only possessed biologically
meaningful fold changes with a magnitude of at
least 2, but also took into account the variability
of observed fold changes and reached statistical
significance.
Example 2: assessment of agreement
Liao et al15 used the dataset of Dobbin et al9 to
demonstrate the application of CCC to the as-
sessment of agreement between two technical
replicates of samples of five cell line pellets at
each of four laboratories (Lab 615, Lab 616, Lab
617, Lab 618). The array platform used was the
Affymetrix Human Genome U133A arrays. Due
to the importance of the expression levels of the
housekeeping genes for quality control of the data
derived from microarray experiments, the nor-
malized intensities on the log2 scale from 100
housekeeping genes of cell line H1437 obtained
from each of the four laboratories were used in
the analysis.
The results for evaluation of agreement of the
expression levels between two replicates within
each laboratory by the asymptotic and the GPQ
methods are presented in the Table. The CCC
ranged from 0.9775 in Lab 617 to 0.9918 in Lab
616. The 95% lower confidence limits on the log2
scale by both the GPQ and asymptotic methods
were almost identical to the third decimal point
for all four laboratories. In addition, all 95% lower
confidence limits by both methods were > 0.90
for the four laboratories. Therefore, if the minimal
threshold of CCC for agreement was set at 0.90,
then one can claim that at the 5% significance level,
the expression levels of technical replicates for the
100 housekeeping genes of cell line H1437 met
the minimal requirement of quality control for
agreement for all four laboratories. In other words,
for the 100 housekeeping genes, an excellent agree-
ment existed between the two technical replicates
at all four laboratories.
Reproducibility of simulation results
The results of our simulation studies indicated
that the performance of both MLS and GPQ ap-
proaches was very similar with respect to proba-
bility coverage, type I error rate and power. For
example, the probability coverage of the 95% con-
fidence intervals constructed by both MLS and
GPQ methods was at least 95%. This phenome-
non also implied that both methods were con-
servative in their assessment of reproducibility
between laboratories. In other words, the type I
error rate for falsely claiming to meet the mini-
mal threshold of reproducibility was in fact below
the nominal 5% level. Figure 3 presents the power
curves of both MLS and GPQ methods when the
minimal threshold of reproducibility was 0.5, and
the numbers of laboratories and samples were
equal to 10. Figure 3 reveals that although the
difference in power was relatively small, the GPQ
approach was uniformly more powerful than the
MLS method.
Discussion
Quality performance of GCBCs is vital to the suc-
cess of translational medicine. A well-performed
GCBC can not only accurately predict the clinical
outcomes of patients, but also optimize the treat-
ment for each patient based on his or her own
clinical or pharmacogenomic characteristics, to
achieve the goal of personalized medicine. Three
of the most important elements in quality per-
formance of GCBCs are selection of truly differ-
entially expressed genes, agreement of expression
Table. Concordance correlation coefficient based
on log2 intensity by method and laboratory
95% lower confidence 
limitLaboratory Estimate
Asymptotic Exact
615 0.9862 0.9809 0.9804
616 0.9918 0.9886 0.9885
617 0.9775 0.9694 0.9687
618 0.9867 0.9820 0.9817
Reproduced with permission from Liao et al.15
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levels between technical replicates of the same
samples obtained under the same operating con-
ditions, and reproducibility between laboratories.
We proposed criteria for evaluation of quality per-
formance with respect to the three elements. Based
on the suggested criteria, we formulated statisti-
cal hypotheses and proposed statistical methods
with respect to each element. Simulation results
and applications to real data demonstrated that
the proposed hypotheses and statistical methods
are an adequate approach for evaluation of qual-
ity of GCBCs, with respect to selection of truly
differentially expressed genes, agreement and 
reproducibility.
Sensitivity, specificity, positive predictive value,
negative predictive value, and area under the re-
ceiver operating characteristic (ROC) curve are
other quality measures for evaluation of accuracy
of GCBCs.19,20 However, most of the current
methods for statistical inference using the area
under the ROC curve are derived based on a sin-
gle biomarker. GCBCs, on the other hand, are 
in vitro diagnostic devices composed of multiple
biomarkers or genomic markers. In addition, even
for the prognosis or prediction of the same clini-
cal outcome, the number of genomic markers is
different from one GCBC to another. Therefore,
evaluation of quality performance for a single
GCBC, choice of thresholds for prognosis, and
medical decision or comparison of accuracy be-
tween GCBCs based on area under the ROC curve
turn out to be more complicated and require fur-
ther research.
MammaPrint® is a qualitative in vitro diag-
nostic test that uses the expression profile of 70
genes from fresh frozen breast cancer tissue sam-
ples, based on microarray technology, to evalu-
ate the risk of distant metastasis in patients with
node-negative breast cancer.21–24 The area under
the ROC curves for time to distant metastases at
5 years and overall survival at 10 years are 0.681
and 0.648. In addition, the positive predictive
value is only 0.22 for metastatic disease at 5 years.
In other words, 78% of patients with a positive
result by MammaPrint® will not have metastatic
disease at 5 years. Although it is approved by the
US FDA, the accuracy of MammaPrint® is, at best,
mediocre. One of the possible reasons for the
middling performance of MammaPrint® is that
the duration for prognosis or prediction is 5–10
years. Many medical advances, such as introduc-
tion of a new effective treatment, can take place
during such a long period. Therefore, research on
the study design and analyses for evaluation 












Figure 3. Power curve for testing the hypothesis that between-laboratory reproducibility (r) is > 0.5. Solid curve = GPQ
method; dashed curve = MLS method.
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Disclaimer
The views expressed in this article are the personal
opinions of the authors and may not necessarily
represent the position of National Taiwan
University, and the National Health Research
Institutes, Taiwan.
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